Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬-溶酶体系统来阻止胰腺癌
基本信息
- 批准号:10358483
- 负责人:
- 金额:$ 36.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffinityAntigen PresentationAutophagocytosisAutophagosomeBRCA1 geneBindingBiochemistryBiogenesisCell LineCell membraneCell surfaceCellsComplexCoupledEndoplasmic ReticulumEnsureEpithelialEvolutionExcisionGeneticGoalsGolgi ApparatusGrantGrowthHumanImmuneImmune EvasionImmunofluorescence ImmunologicIn VitroLocationLysosomesMajor Histocompatibility ComplexMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMolecularMolecular GeneticsMusNeoplasm MetastasisNormal CellOrganellesPancreasPancreatic Ductal AdenocarcinomaPancreatic Intraepithelial NeoplasiaPathway interactionsPatientsPeptidesPost-Translational Protein ProcessingProteinsProteomicsPublicationsRecyclingRoleRouteSamplingSpecimenStainsSurfaceSystemT-LymphocyteTestingTissue BanksTumor TissueUbiquitinWorkbasecancer cellfitnessgenetic approachimmune checkpoint blockadeimmunogenicityin vivometabolic fitnessmouse modelnovelpancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpeptide Iprotein degradationreceptortraffickingtumorubiquitin ligase
项目摘要
PROJECT SUMMARY
Cancer cells co-opt autophagy - an evolutionarily conserved cellular recycling pathway - to maintain
metabolic fitness. Prior studies have shown that Pancreatic Ductal Adenocarcinoma (PDA) up-regulates
autophagy and lysosomes – acidic organelles where autophagic cargo is degraded – to dramatically increase
the bulk breakdown and recycling of diverse intracellular substrates. An additional, less well understood
function of autophagy is the selective removal of specific proteins in order to endow PDA cells with
enhanced fitness.
We now show that the autophagy-lysosome pathway selectively targets major histocompatibility
complex class I (MHC-I) protein for degradation as a mechanism of immune evasion. Through affinity-
based capture of intact lysosomes (LysoIP) from normal and PDA cell lines coupled with proteomics-based
analysis, we identified MHC-I as a significantly enriched lysosomal substrate in PDA cells. Consistent with this
finding, immuno-fluorescence staining demonstrates that, unlike normal cells where MHC-I localizes to the
plasma membrane (PM), in PDA cell lines and primary patient PDA specimens, MHC-I is trapped inside
autophagosomes and lysosomes. Importantly, tumor-specific suppression of autophagy is sufficient to 1)
stabilize and re-localize MHC-I to the PM, 2) increase antigen presentation and 3) boost T cell mediated tumor
killing in vitro and in vivo. Building on these findings the goal of this study is to determine the molecular
mechanisms underlying aberrant MHC-I trafficking, and to identify targetable nodes that can be manipulated to
restore MHC-I on the cell surface of PDA cells. Our revised application will leverage the combined power of
biochemistry, genetics, organelle purification and proteomics, a novel mouse model and patient PDA samples
to address the following specific aims: 1) determine how post-translational modifications of MHC-I cooperate
with the autophagy machinery to facilitate capture by autophagosomes, 2) identify where along its trafficking
route is MHC-I diverted to autophagosomes and 3) determine when during the course of PDA evolution does
MHC-I dysregulation occur and can we exploit this information to establish more effective strategies to enhance
antigen presentation and immune mediated tumor killing.
In summary, our discovery of autophagy dependent degradation of MHC-I highlights an important new
paradigm for immune evasion in PDA and potentially other cancers. Findings from our proposed studies will
determine key molecular mechanisms underlying MHC-I dysregulation and establish new nodes that can be
targeted to restore antigen presentation in PDA.
项目总结
癌细胞选择自噬--一种进化上保守的细胞循环途径--来维持
新陈代谢健康。先前的研究表明,胰腺导管腺癌(PDA)上调表达
自噬和溶酶体--自噬货物被降解的酸性细胞器--急剧增加
不同胞内底物的整体分解和回收。另一个不太为人所知的
自噬的功能是选择性地去除特定的蛋白质,以便赋予PDA细胞
增强了体能。
我们现在表明,自噬-溶酶体途径选择性地针对主要组织相容性。
复合I类(MHC-I)蛋白作为免疫逃避的一种降解机制。通过亲和力-
基于蛋白质组学的正常和PDA细胞系完整溶酶体(LysoIP)捕获
分析表明,MHC-I是PDA细胞中显著丰富的溶酶体底物。与此一致
发现,免疫荧光染色表明,与正常细胞不同,MHC-I定位于
质膜(PM),在PDA细胞系和原发患者的PDA标本中,MHC-I被困在里面
自噬小体和溶酶体。重要的是,肿瘤特异性的自噬抑制足以1)
稳定和重新定位MHC-I到PM,2)增加抗原提呈,3)促进T细胞介导的肿瘤
在体外和体内杀死。基于这些发现,这项研究的目标是确定分子
MHC-I异常贩运的潜在机制,并确定可被操纵的靶向节点
在PDA细胞表面恢复MHC-I。我们修订后的应用程序将利用
生物化学、遗传学、细胞器纯化和蛋白质组学、一种新的小鼠模型和患者PDA样本
为了解决以下具体目标:1)确定MHC-I的翻译后修改如何合作
利用自噬机制来促进自噬捕获,2)识别其贩运的地点
MHC-I途径被转移到自噬体内,3)确定在PDA进化过程中何时发生
MHC-I失调的发生,我们是否可以利用这些信息来建立更有效的策略来增强
抗原提呈和免疫介导的肿瘤杀伤。
总之,我们发现的依赖自噬的MHC-I降解突出了一个重要的新的
PDA和其他潜在癌症的免疫逃逸范例。我们建议的研究结果将
确定MHC-I失调的关键分子机制并建立新的节点
目标是恢复PDA中的抗原呈递。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rushika Miriam Perera其他文献
Rushika Miriam Perera的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rushika Miriam Perera', 18)}}的其他基金
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬溶酶体系统来阻止胰腺癌
- 批准号:
10212065 - 财政年份:2021
- 资助金额:
$ 36.49万 - 项目类别:
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬-溶酶体系统来阻止胰腺癌
- 批准号:
10590682 - 财政年份:2021
- 资助金额:
$ 36.49万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10594038 - 财政年份:2021
- 资助金额:
$ 36.49万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10186267 - 财政年份:2021
- 资助金额:
$ 36.49万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10370440 - 财政年份:2021
- 资助金额:
$ 36.49万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10404053 - 财政年份:2020
- 资助金额:
$ 36.49万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10626914 - 财政年份:2020
- 资助金额:
$ 36.49万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10252885 - 财政年份:2020
- 资助金额:
$ 36.49万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
9974205 - 财政年份:2020
- 资助金额:
$ 36.49万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Continuing Grant